Stereospecific and nonstereospecific effects of (+)- and (-)-morphine: evidence for a new class of receptors?

Non-stereospecific excitatory actions of morphine may be due to GABA-A receptor blockade

An explosive motor behavior (EMB) similar to that seen following morphine injection into the rat periaqueductal gray (PAG) was observed following an injection of GABA-A receptor antagonists into the rat PAG. In general, the potencies of certain opiates and known GABA-A antagonists in producing EMB following their injections into the PAG paralleled their potencies as GABA antagonists in a radioreceptor assay. We suggest that one of the dual actions of morphine in the CNS may be GABA blockade.

Opiate receptors: an introduction

Current status of opiate receptors and their agonists is reviewed--basic aspects of receptor theory, the importance of stereospecificity in drug-receptor interactions and the role of 'second messengers' in drug action. The three classes of endogenous opioids, originating from three distinct genes, are discussed: pro-opiomelanocortin, giving rise to beta-endorphin, ACTH and various MSHs; pro-enkephalin, giving methionine enkephalin and leucine enkephalin; and prodynorphin; their anatomical distribution and the main classes of receptors with which they interact, the mu-receptor, with a high affinity for met-enkephalin and beta-endorphin (as well as morphine and dynorphin A); the delta-receptor for which the primary ligand is leu-enkephalin; and the kappa-receptor which is the main target for the dynorphins. Functional roles for endogenous opioids are considered. Essentially they are inhibitory to target neurones, depressing motor reflexes, baroreflexes and nociception. They also have roles in the response to physical and psychological stress.

Inhibition of enkephalinase activity attenuates naloxone-precipitated withdrawal symptoms

In this study we examined the effects of the enkephalinase inhibitor, thiorphan, on the naloxone-precipitated withdrawal syndrome in chronic morphine dependent rats. Intracerebroventricular administration of thiorphan (40 micrograms/2 microliter) in morphine dependent rats, inhibited the severity of the naloxone-precipitated abstinential syndrome. Administration of thiorphan (20 micrograms/0.5 microliter) in the periaqueductal grey matter of morphine dependent rats, in addition to explosive motor behaviour and ipsilateral rotation, also significantly suppressed most of the naloxone-precipitated withdrawal symptoms. It is suggested that a decreased biotransformation of endogenous opioid peptides might replace the relative shortage of morphine during withdrawal in opiate addicted subjects and attenuate the abstinence symptoms.

Action of morphine on rat cortical neurons intracellularly recorded in vivo: evidence for an excitatory postsynaptic effect which is naloxone insensitive

The action of morphine, applied either iontophoretically (40-200 nA balanced current) or systemically (5-10 mg/kg, intraperitoneally) to rat cortical neurons, was investigated in vivo, using intracellular electrodes. Morphine increased the apparent input resistance and increased the number of both spontaneous and evoked action potentials. Several cells, which normally generated single spikes, generated bursting potentials; neurons with bursting activity increased their activity. Naloxone, iontophoretically or systemically applied, did not reverse or prevent the morphine-induced excitation. The iontophoretic administration of cadmium suggested that the effects of morphine were due, at least in part, to a postsynaptic site of action. It is suggested that the increase of cellular excitability induced by morphine could contribute to its production of seizures in cortex.

Pharmacological effects of 1,2,3,5,6,10b-hexahydropyrido[2,3g]indolizine, a bridged-nicotine analog

The racemate of a bridged-nicotine (BN) analog was synthesized and resolved into its enantiomers for pharmacological comparisons to (+)- and (-)-nicotine. The EC50 values for (-)- and (+)-nicotine and (-)- and (+)-BN were 4, 170, 53 and 400 microM, respectively, for producing contractions of guinea-pig ilea. (-)-Nicotine was an effective antinociceptive agent in the mouse tail-flick procedure at i.v. doses of 0.1-0.3 mg/kg, whereas the isomers of BN failed to alter tail-flick response in doses up to 5 mg/kg. (-)-Nicotine (0.01-0.3 mg/kg, i.v.) increased blood pressure and decreased heart rate in anesthetized rats. Neither (+)- nor (-)-BN altered blood pressure and heart rate in rats in this dosage range. At doses of 3-100 mg/kg, (+)-BN produced an increase in blood pressure without changing heart rate, while (-)-BN decreased both blood pressure and heart rate. Bridging the pyrrolidine and pyridine rings decreased biologic activity and did not result in stereoselectivity greater than that observed with (+)- and (-)-nicotine. It appears that there may be subpopulations of nicotine receptors to which the isomers of BN do not interact.

Narcotic withdrawal in the emergency department

Patients in narcotic withdrawal can be very disruptive in an emergency department. An understanding of the dynamics of narcotic addiction and withdrawal is useful for the emergency physician. Narcotics are used for the euphoria they provide; however, chronic use results in physiological and psychological changes. Research into the endorphin system has provided a model of narcotic addiction and withdrawal. Effective therapies now exist for use in the emergency department.

Different pattern of association of beta-endorphin and cortisol responses to dextroamphetamine in postmenopausal women and young men

A negative correlation between plasma beta-endorphin and cortisol responses to 0.15 mg/kg dextroamphetamine i.v. was found in a group of seven normal postmenopausal women, while the responses of the two hormones were positively correlated in nine normal young men. These results suggest that even though the adrenocorticotropic hormone (ACTH)-cortisol and beta-endorphin are usually regulated by the same mechanism (both ACTH and beta-endorphin are derived from proopiocortin), there are situations in which these systems can be associated in a different pattern. The elucidation of these situations may contribute to the understanding of regulatory mechanisms of the two systems.

Effect of ascorbate on the toxicity of morphine in mice

The effects of ascorbic acid on the toxicity of morphine in mice were investigated. An intraperitoneal dose of sodium ascorbate (1 G/kg) injected 10 min prior to morphine (500 mg/kg, i.p.) was found to provide significant protection against mortality due to respiratory depression, while having no effect on the lethality of the pentobarbital. Pretreatment with ascorbate had no effect on the distribution of morphine in brain tissue, nor did it alter the pH of the plasma. Administration of ascorbate in vivo also produced no inactivation of binding to opioid receptors. It is postulated that ascorbate antagonizes the lethality of morphine by selectively affecting neuronal activity.

The biochemical and behavioral effects of phospholipase A2 and morphine microinjections in the periaqueductal gray of the rat

In order to characterize the in vivo action of phospholipase A2 (PLA2) on opiate receptors and opiate-induced behaviors, the effects of injections of PLA2 into the periaqueductal gray region (PAG) of the rat were assessed on free fatty acid (FFA) release, opiate-binding levels, and morphine-induced behaviors. Rats received bilateral PAG injections of 2 micrograms of PLA2 while anesthetized. One hour later, regions around the cannulae tracts in PLA2-treated rats contained over 2.5 times more FFA than saline-injected controls, and 3H-dihydromorphine binding was reduced on average more than 70%. In another series of experiments, conscious rats were given 2 micrograms of PLA2 prior to 10 micrograms of morphine through cannulae chronically implanted into the PAG. PLA2 did not significantly attenuate morphine-induced analgesia as measured by the tail-flick test to radiant heat, but did prevent the explosive motor behavior observed following morphine injections alone. PLA2 by itself did not induce analgesia, but did cause explosive motor behavior 2 hr after the injections. Neither lysophosphatidylcholine nor trypsin resulted in motor seizures following PAG injections. It was concluded that the behavioral effects of PLA2 result from the unique properties of the enzyme, rather than generalized membrane damage, and that the opioid sites and mechanisms that mediate analgesia are different from those associated with explosive motor behavior.

3-[18F]Acetylcyclofoxy: a useful probe for the visualization of opiate receptors in living animals

A fluoro-analogue of the potent narcotic antagonist, naltrexone, was synthesized and shown to bind with high affinity to opiate receptors in vitro. 3-[18F]acetylcyclofoxy was prepared via a one-step triflate displacement reaction with the positron emitting 18F ion from tetraethylammonium [18F] fluoride. 3-[18F]acetylcyclofoxy accumulation in opiate receptor rich brain regions of both rat and baboon is shown to be completely displaced by the active enantiomer of naloxone [-)-naloxone) while the identical dose of the pharmacologically inert (+)-naloxone has no detectable effect. Moreover, both rat and baboon brain showed the well documented, typical opiate receptor distribution so that basal ganglia and thalamus are clearly visible in the living baboon brain up to 95 min after intravenous injection of 3-[18F] acetylcyclofoxy. We expect that 3-[18F )acetylcyclofoxy will be a useful probe for visualizing opiate receptors in living humans.

Behavioral effects of morphine, levorphanol, dextrorphan and naloxone in the frog Rana pipiens

Systemic morphine induces explosive motor behavior and generalized muscular rigidity in frogs. Naloxone does not reverse either of these effects of morphine but at high doses causes muscular flaccidity and unresponsiveness to stimulation. Intraspinal morphine induces rigidity, but not explosive motor behavior, and this action is blocked by naloxone. Behavioral effects are seen rarely after intraspinal levorphanol (rigidity) and never after intraspinal dextrorphan or naloxone. In contrast to systemic morphine and naloxone, systemic levorphanol and dextrorphan are lethal to frogs at high doses.

Naloxone blocks the analgesic action of levorphanol but not of dextrorphan in the leopard frog

Intraspinal injection of levorphanol (3 micrograms) at the lumbar area of the leopard frog, Rana pipiens, induced analgesia which was completely blocked by co-injection of naloxone (3 micrograms), whereas dextrorphan (3 micrograms) induced analgesia which was unaffected by naloxone. Subcutaneous levorphanol (20 or 80 mg/kg) induced a dose-dependent analgesia which was blocked by concurrent naloxone (2 mg/kg), while only the higher dose of dextrorphan (80 mg/kg) induced analgesia which was unaffected by concurrent naloxone at 8 or 80 mg/kg. These data are the first to indicate naloxone-insensitive, dextrorphan-induced analgesia.

Naloxone-induced augmentation of the photically evoked afterdischarge in conscious rats

Naloxone, at subconvulsive dose levels, from 1 to 15 mg/kg were administered to conscious rats. Significant increases in photically evoked afterdischarge occurrence were seen at naloxone dose levels above 5 mg/kg with no clinical evidence of seizure activity being observed. Typically photically evoked afterdischarge augmentation is only observed following the administration of convulsive drugs.

Angular dependence of the interaction energy between the N lone pair of amines and a proton: relevance to drug-receptor systems

Ab initio molecular orbital calculations with a 4-31G basis set have been performed to study the angular dependence of the interaction energy between a lone electron pair of nitrogen and a proton. In this study ammonia and trimethylamine were used as models of biologically active amines. A proton was used as a model of an electrophilic site at the receptor. Results obtained confirm previous indications that the energy required to bend the proton from the lone pair direction decreases markedly as the two species are further separated from one another. Implications regarding the interactions of drugs and hormones at specific receptors are discussed.

Effect of high doses of naloxone on shuttle avoidance acquisition in rats

Administration of high doses of naloxone intraperitoneally (2.5-10.0 mg/kg) resulted in a dose-related impairment of avoidance response acquisition in a shuttle avoidance paradigm in rats. Naloxone in this dose range produced a significant decrease in the number of intertrial responses but did not result in a significant dose-response. Escape latencies were not affected by naloxone administration at any dose tested. The effect of naloxone on activity and nociception are implicated as possible causes of the observed behavior. The results are discussed as behavioral evidence supporting theories postulating multiple opiate receptors.

Morphine-induced analgesia and explosive motor behavior in an amphibian

Morphine sulfate is a weak analgesic in the frog Rana pipiens pipiens, causing a slight increase in nociceptive threshold at a dose of 10 mg/kg and a pronounced increase at 100 mg/kg. Morphine-induced analgesia persists for at least 165 min and is significantly attenuated by naloxone. The analgesic doses of morphine are well below the lethal dose and are without noticeable effect on the behavior of the frogs or their responses to non-painful stimuli. Higher doses of morphine (320 and 640 mg/kg) induced a state of hyper-responsiveness to sensory stimuli similar to the explosive motor behavior induced in rats by microinjection of morphine into the periaqueductal gray.

Facilitation of an operant task in the rat following injection of whole brain extract

It has been shown that the administration of trained donor brain extract to naive rats results in facilitation of performance on the same task. In the present study a group of food deprived rats was trained to press a lever for food on a continuous schedule of reinforcement until they reached criterion. The animals were then sacrificed, their brains excised, homogenized and the small proteins (m.w. less than 3500) extracted. A group of untrained rats was also sacrificed and their brains extracted. Three groups of rats were used as recipients, receiving either trained donor or untrained donor brain extract or saline. The animals were tested individually for one-hour sessions at 18, 42 and 66 hours after the injection. The number of bar presses made by each rat was noted and the group mean plus or minus the standard deviation were calculated for each session. The results of a one-way analysis of variance showed that the group which received trained donor brain extract performed at a higher rate than either control group. These data suggest that some factor, (specific or non-specific), associated with the task has been transferred.

Effects of leucine5 - and methionine5 - beta h - endorphin on behavior and electroencephalogram in cats

Intracerebroventricular administration of leu5 - and met5 - beta h - endorphin produces sequential behavioral changes characterized by restlessness, eye fixation, head tremor, and exaggerated orienting reaction to external auditory stimuli, accompanied by EEG alterations. These changes take place during three stages. Met5- produces an increase in amplitude and reactivity of the theta rhythm in the hippocampus. Leu5- produces a masking of the theta rhythm by the appearance of spiking activity. Leu5- produces a loss of reactivity to visual stimuli not observed with met5-. The exaggerated reaction to auditory stimuli accompanied by an increased response of the reticular formation indicates a sensitivity of some mesencephalic structures (concerned with the modulation of sensory input) to both endorphins. Naloxone blockade of the subcortical (limbic) activity prominent in Stage II reveals the persistence of the first seen Stage I characteristics. These reticular-neocortical effects persist also into Stage III where they are seen intermixed with the limbic effects most prominent in Stage II. This suggests the presence of two endorphin-sensitive neural systems, only one of which is Naloxone reversible, and is that which in the cat covaries with the excited, hyperattentive state rather than the sedation and immobility phase seen in the rat. This dual system is compared to that described by Jacquet (13).

Dual actions of morphine on the central nervous system: parallel actions of beta-endorphin and ACTH

In the studies described above, the intracerebral microinjection technique was used to study the actions of morphine at morphine-sensitive sites, the periaqueductal gray (PAG) and the midbrain reticular formation (MRF). In the PAG, morphine exerted dual actions: inhibitory and excitatory. In the MRF, morphine exerted an excitatory action only, indicating that the dual actions of morphine are dissociable and site specific. Following microinjection into the PAG, beta-endorphin exerted an inhibitory, and ACTH an excitatory, action, i.e., each duplicated one of morphine's dual actions. These results indicated that receptors for the endogenously occurring peptides, beta-endorphin and ACTH, may play a role in morphine's potent pharmacological actions. Although these studies do not shed direct light on the physiological role of these neuropeptides and their receptors, nor on their potential roles in the functional regulation of brain (especially in diseased mental states), it may be permissible to offer some speculations. We previously proposed that beta-endorphin may be an endogenous antipsychotogen, and that a deficiency in brain beta-endorphin may underlie some forms of psychopathology. In view of beta-endorphin's biosynthetic link to ACTH, and the behavioral effects of beta-endorphin (sedated immobility) that was found to be opposite in kind to those of ACTH (fearful hyperreactivity) following administration into brain, it is possible that these two neuropeptides may have regulatory roles in maintaining a functional balance in brain. (It may be speculated that these biosynthetically linked neuropeptides served survival functions of "flight" and "freeze" in our evolutionary ancestors.) An imbalance in the bioavailability of either of the two neuropeptides, e.g., a deficiency of beta-endorphin or an excess of ACTH (perhaps due to the lack of the specific enzymes that cleave these peptides from their parent prohormone) may be an etiological factor in some forms of chronic functional disorders of the brain.

Naloxone-induced epileptogenesis has brain-site specificity in rats

Naloxone injected into the lateral septum caused intense electrocortical seizures which did not occur following callosal or periaqueductal gray (PAG) injections. Conversely, injections into periaqueductal gray caused a characteristic and pronounced backward circling with only moderate electrocortical changes. Intracerebral injection of naloxone had effects, including epileptogenesis, which appeared to be site-specific. These effects are in some ways similar to the effects of enkephalin and morphine.

Peptidase inhibitors reduce opiate narcotic withdrawal signs, including seizure activity, in the rat

Narcotic withdrawal was precipitated by administration of naloxone in a low dose at 2 h after the final dose of morphine in a 9-day dependency-inducing schedule. Withdrawal was characterized by leaps, increased nocifensor activity and by cerebral cortical epileptiform activity, the latter not generally reported to be prominent in narcotic withdrawal. Single large doses of morphine did not provoke epileptiform activity at 2 h postinjection but did induce an acute opioid dependency wherein a moderately high dose of naloxone, ineffective in non-dependent rats, provoked upward leaping and electrocortical epileptiform activity. Pretreatment of the 9-day dependent rats with peptidase inhibitors, administered intracerebroventricularly, significantly reduced withdrawal severity including the epileptiform activity. We propose that peptidase inhibitors protect certain species of endogenous opioids and/or other neuropeptides that tend to suppress expression of the narcotic withdrawal syndrome. Furthermore, our findings suggest that epileptiform activity is a nascent form of cerebral activity hitherto largely unnoticed in narcotic withdrawal and that neuropeptides may be involved in certain epileptic states.

Reinforcing effects of brain microinjections of morphine revealed by conditioned place preference

The previously documented place conditioning paradigm was used to study the reinforcing effects of cerebral microinjections of morphine. Rats with implanted cannulae experienced place conditioning procedures, involving morphine administration into the IV (0.5 or 10 microgram), III (10 microgram) or lateral (0.5-10 microgram) ventricles. Positive reinforcement, indicated by a significant preference for the place paired with morphine compared to the place similarly paired with control treatment, was seen in rats given 10 microgram morphine into the lateral ventricle. The rats given 10 microgram into the III ventricle also showed a preference, but the effect was not statistically significant. Positive reinforcement was subsequently demonstrated with morphine microinjections (10 microgram) into the lateral hypothalamus, periaqueductal gray or nucleus accumbens. No clear preferences were produced by morphine injections into the caudate-putamen, amygdala or nucleus ambiguus. Following the final place conditioning test, rats were re-administered the treatment dose and analgesia and body temperature were measured. All three sites associated with reinforcement evidenced hyperthermia, but only the periaqueductal gray evidenced a short-latency analgesia. Sites with null place conditioning were not associated with any major behavioral effects. Using (+) and (-)-morphine (10 microgram), it was demonstrated that only the active (-)-stereoisomer was effective in producing place preferences after injection into the periaqueductal gray. It was concluded that morphine administered directly into parts of the rat brain can produce place conditioning similar to that seen after systematically administered morphine. Morphine-produced place preference is not related to the acute depressant aspects of morphine, but may be related to the stimulant aspects.

Stereoselectivity of opiate antagonists in rat hippocampus and neocortex: responses to (+) and (-) isomers of naloxone

The relative potencies of the (+) and (-) isomers of naloxone in antagonizing electrophysiological responses to D-alanine2-methionine enkephalinamide were compared in rat frontal cortex and hippocampus. In the in vitro hippocampus, the (-) isomer was found to be at least a 100 times more potent than the (+) isomer in antagonizing opiate-induced changes in field potentials. Similar stereoselectivity was observed in vivo in both frontal cortex and hippocampus in terms of the antagonism of enkephalin-induced changes in spontaneous cell firing. The direct effects of (+) and (-)-naloxone were examined as well. In hippocampus both in vivo and in vitro, no differential effect was observed, whereas in the neocortex (-)-naloxone was considerably more potent than the (+) isomer in eliciting depressions of spontaneous activity. These direct effects of naloxone in the cortex do not appear to be due to an antagonism of the effects of endogenously released opioids. These results demonstrate that the stereoselectivity of naloxone isomers in antagonizing electrophysiological responses to opiates in the cortex and hippocampus parallels that previously observed in other brain regions and in other tissues. In addition, they suggest that naloxone may have interactions with other unknown opiate (or possibly non-opiate) receptors which are of physiological significance.

Hyperactivity versus explosive motor behavior induced by opioids in the rat. Mechanisms elucidated with enkephalin-tyrosine-o-sulfate and morphine congeners

A relatively mild hyperactive state (HAS), characterized by agitation and hypermotility, is induced by opiate drugs and opioid peptides in general and is blocked by naloxone. HAS can be distinguished from the profound hyperresponsiveness of an explosive motor behavior (EMB). Sulfation of the phenolic moiety in morphine or in methionine enkephalin essentially abolishes opiate receptor binding activity. The sulfated peptide lacks detectable pharmacological activity in the rat, whereas sulfated morphine is several hundred-fold more potent than morphine in eliciting (EMB). Thus, EMB is elicited only by congeners of morphine having appropriate hydrophilic substitution at C-6 and which is mediated through a receptor that is insensitive to naloxone.

Differentiation of agonist conformation and antagonist conformation in multiple opioid receptors

To differentiate the opiate (naloxone) receptor and the enkephalin receptor in rat brain, we solubilized the receptor molecules by detergent and determined the molecular weights by gel filtration. The receptor preparation was bound to [3H] naloxone or [3H] Met5-enkephalin, and was solubilized by Triton X-100. On gel chromatography with a Sepharose 6B column, the agonist and the antagonist conformation of opioid receptors eluted as molecules with the molecular weights of 240,000, and 120,000 and with Stokes' radii of 5.5 nm and 4.3 nm, respectively. Further, it was also disclosed that Na+ was bound to the antagonist conformation of opioid receptors but not to the agonist conformation.

Nicotine binding sites and their localization in the central nervous system

The resolution of racemic nicotine to provide optically pure (+)-nicotine and the synthesis of radiolabeled nicotine with high specific activity have facilitated the study of nicotine binding in brain. The actions of the stereoisomers of nicotine on the central nervous system are qualitatively similar in most tests but (-)-nicotine is more potent than the unnatural (+)-isomer by 10-fold or greater. Binding of radiolabeled nicotine to brain has both saturable and nonsaturable components. Only saturable binding is affected by incubation conditions such as time, temperature, pH and ion concentration. Excess concentrations of the stereoisomers are equally effective in displacing (-)-[3H]-nicotine from brain homogenates. Nevertheless, a direct comparison of (+)-[3H]-nicotine and (-)-[3H]-nicotine binding shows that the latter has a KD three times lower than the former. (-)-[3H]-Nicotine is bound to the greatest degree in hypothalamus and hippocampus, areas that also exhibited the most stereoselectivity for nicotine. However, differences in the binding affinities of the two isomers were far less than the pharmacological stereospecificity observed.

Behavioural effects of GABA-agonists and antagonists infused in the mesencephalic reticular formation - deep layers of superior colliculus

Unilateral infusion of GABA-receptor antagonists (picrotoxin, bicuculline) in the mesencephalic reticular formation-deep layers of the superior colliculus (MRF-DLSC) elicits tight head-to-tail contralateral posturing but not active circling. Bilateral infusion of the GABA antagonists in the MRF-DLSC elicits compulsive gnawing and biting but not licking or sniffing. Infusion of GABA-receptor agonists (muscimol, THIP) in the MRF-DLSC while producing only minor or no motor or behavioural effects, drastically altered apomorphine effects; thus, unilateral infusion of muscimol resulted i tight, head-to-tail ipsiversive circling while bilateral infusion of muscimol converted the apomorphine-syndrome from stereotypy of high-intensity into pure compulsive forward locomotion devoid of sniffing. The results indicate that GABAergic mechanisms in the MRF-DLSC are of primary importance in the expression of motor and behavioural syndromes arising from the striatum.

Stereoselective effects of opiate agonists and antagonists on ingestive behavior in rats

In male Sprague Dawley rats, the (-)-isomer of the opiate antagonist GPA 1843 (beta-9-methyl-5-phenyl-2-allyl-2'-hydroxy-6, 7-benzomorphan) produced dose-related decreases in nocturnal feeding and of hyperphagias induced by 2-deoxy-D-glucose (2-DG; 400 mg/kg) and 24 hr food deprivation (FD). The hyperphagia induced by insulin (10 U/kg) was not significantly decreased by GPA 1843. In contrast, comparable doses of the (+)-stereoisomer, GPA 1847, had no effect on nocturnal, 2-DG or FD hyperphagia. In addition, hyperphagia and hyperdipsia were observed following administration of the opiate agonist levorphanol, but not its stereoisomer, dextrorphan. Thus, the effects of these agents on consummatory behavior are mediated by a stereospecific interaction with opiate receptors, which further indicates that endogenous opiate peptides are involved in the expression of these opiate-related hyperphagias.

Morphine conditioned taste aversion reversed by periaqueductal gray lesions

The role of the periaqueductal gray (PAG) in morphine conditioned taste aversion (CTA) was studied using male Wistar rats as subjects. Following the presentation of a novel saccharin solution, animals with or without a lesion of the PAG were intraperitoneally injected with either morphine, lithium, ethanol or fenfluramine. As evident by the amount of saccharin solution consumed on a subsequent presentation, a PAG lesion reversed a morphine CTA but not CTAs produced by the other drugs used. The results suggest that the PAG may in part mediate morphine CTA.

Morphine and ACTH1-24: correlative behavioral excitations following micro-injections in rat periaqueductal gray

Rats implanted with bilateral cannulas in the periaqueductal gray exhibited similar behavioral excitations following microinjections of morphine sulphate and ACTH1-24. Injections were more effective when the sites were located within rather than below the periaqueductal gray. Analgesia was observed following morphine but not ACTH microinjection. These results confirm that morphine exerts a dual action, inhibitory (i.e. analgesic) and excitatory, with ACTH mimicking only the latter action.

Intrathecal high dose morphine produces hyperalgesia in the rat

Intrathecal microinjections of high doses of morphine in the rat produce algesia, hyperalgesia and hypersthesia as opposed to the analgesia found at lower doses. This hyperalgesia is not naloxone reversible and is only partially stereospecific. Morphine-3-glucuronide produces the hyperalgesia at low doses. This morphine-hyperalgesia may be mediated by a class of receptors similar to that which produces opiate-induced central excitation.

Morphine differentially affects ventral tegmental and substantia nigra brain reward thresholds

In order to differentiate the roles of the nigrostriatal and mesolimbic-mesocortical dopamine systems in the action of opiates on dopaminergically mediated intracranial self-stimulation (ICSS), the effects of chronic morphine administration and acute naloxone administration on ICSS were tested in rats with electrode placements in the substantia nigra pars compacta (A-9) and the ventral tegmentum (A-10). Acute morphine (5.0 mg/kg SC) did not affect ICSS thresholds of rats with electrodes in the A-9 nucleus when tested 1, 3, 5, and 23 hours after administration. With repeated daily administration, though, these animals showed increases in thresholds which grew progressively larger with each day of morphine treatment. This threshold elevation was not reversed by naloxone given 0.5 hour after the final morphine treatment on the fifth day. In contrast, acute morphine significantly lowered self-stimulation thresholds in rats with A-10 placements. Tolerance to this facilitatory effect was evident with chronic administration. Naloxone attentuated the lowering of threshold caused by opiate administration in these A-10 animals. The present data suggest a specificity of action of opiates on different brain systems subserving reward and reinforcement. These findings also suggest that the mesolimbic-mesocortical system may play an important role in mediating the rewarding properties of morphine.

Stereospecific dextrorphan tolerance in rats

1 Levorphanol was 20 times more potent than dextrorphan in decreasing food-reinforced fixed ratio 15 responding in male Sprague Dawley rats. 2 Chronic dextrorphan (100 mg/kg, i.p.; every 8 h) resulted in the development of dextrorphan tolerance. The dextrorphan dose-effect curve was shifted to the right three fold. 3 In contrast to dextrorphan, nontolerance developed to the effects of levorphanol. 4 These data support the hypothesis that (+)-isomers of opioids produce pharmacologically distinct CNS effects.

d-Propoxyphene acts differently from morphine on opioid receptor-effector mechanisms

The actions of d-propoxyphene and morphine on opioid receptor mechanisms were compared. In assay measuring receptor binding selectivity in vitro, with dihydromorphine, naloxone and an enkephalin analogue as radioactive ligands, d-propoxyphene differed from morphine in having a higher relative affinity for sites occupied by the peptide. Naloxone was more potent in antagonizing morphine- than d-propoxyphene-induced antinociception in the mouse hot-plate test. In morphine-tolerant mice showing three-fold lower morphine sensitivity the antinociceptive efficacy of d-propoxyphene was unchanged. The results indicate differences in receptor-effector mechanisms between d-propoxyphene and morphine.

Effects of selected opioid agonists and antagonists on DMT- and LSD-25-induced disruption of food-rewarded bar pressing behavior in the rat

Several opioid agonists and antagonists interact with N,N-dimethyltryptamine (DMT) and lysergic acid diethylamide-25 (LSD) in adult male Holtzman rats trained on a positive reinforcement, fixed ratio 4 (FR4) behavioral schedule, i.e., a reward of 0.01 ml sugar-sweetened milk was earned on every fourth bar press. DMT (3.2 and 10.0 mg/kg) and LSD (0.1 mg/kg) given IP with 0.9% NaCl pretreatment, disrupted food-rewarded FR4 bar pressing. Animals were pretreated IP (10--15 min) with predetermined, behaviorally noneffective doses of morphine, methadone, naltrexone, and the (+)- and (-)-enantiomers of naloxone prior to receiving DMT or LSD. Dose-dependent effects were shown with opioid agonist pretreatment. Morphine (0.32--1.0 mg/kg) and methadone (0.32 mg/kg) significantly antagonized the bar pressing disruption induced by DMT and LSD. Larger doses of morphine (3.2 mg/kg) and methadone (1.0--3.2 mg/kg) potentiated only LSD-induced effects, with no effect on DMT-treated groups. The opioid antagonists (-)-naloxone and naltrexone potentiated the disruption of bar pressing induced by DMT and LSD. Failure of (+)-naloxone to potentiate the DMT effects was attributed to a stereo-specific opioid antagonist effect of (-)-naloxone.

Nonspecific excitatory effects of morphine: reverse-order precipitated withdrawal and dose-dose interactions

We recently reported that, in naive mice pretreated with naloxone, morphine can cause withdrawal-like signs that seemingly are not mediated by "opiate" receptors. Such results were confirmed and extended here with another mouse strain. Repetitive vertical jumping could occur respective of injection sequence and depended on dose and dose ratio of the two drugs.

Interactions between morphine and the opioid-like peptides in the rat vas deferens

1 Morphine, methadone, levorphanol, pethidine, etonitazene and related morphine-like alkaloids produced an increase in the electrically-evoked muscular contraction of the rat vas deferens. In contrast, the enkephalins and beta-endorphin caused inhibition of the twitching. 2 The concentration of beta-endorphin required to inhibit by 50% the muscular twitch was about 50 to 100 times less than that of the enkephalins. 3 Pretreatment of the vasa with morphine antagonized the inhibition of the neuromuscular transmission caused by either beta-endorphin or enkephalin. 4 Conversely, pretreatment with beta-endorphin sensitized the vasa to the increase in twitch tension caused by morphine. 5 Morphine did not alter the sensitivity to exogenously administered noradrenaline, dopamine or potassium.

Excitatory and inhibitory effects of opiates in the rat vas deferens: a dual mechanism of opiate action

Both natural (-)-morphine and its unnatural enantiomer (+)-morphine exert an excitatory action on electrically stimulated contractions of rat vas deferens. Preexposure to (-)-morphine results in cross-tolerance to the inhibitory action of beta-endorphin. (-)-Naloxone and its stereoisomer (+)-naloxone also exert an excitatory action, but only (-)-naloxone bocks the inhibtory action of beta-endorphin. Thus morphine exerts a dual action on a peripheral organ: one an inhibitory action mediated by the stereospecific endorphin receptor that is blocked stereospecifically by naloxone, the other an excitatory action mediated by a nonstereospecific receptor that is not blocked by naloxone. The opiate abstinence syndrome is seen as due to the unmasking of the excitatory action of opiates when its concomitant inhibitory influence is removed by selective blockade by naloxone or weakened by selective tolerance. The view that the rat vas deferens is devoid of morphine receptors is now seen as arising from a reverse example of morphine's dual action: the masking of the inhibitory action of morphine by its concomitant and more potent excitatory action.

Depressant and excitant effects of intraspinal microinjections of morphine and methionine-enkephalin in the cat

The effects of intraspinal microinjectins of morphine (10 microgram) and methionine-enkephalin (Met-enkephalin) (5 microgram) on the C-fiber and polysynaptic reflexes in the acute decerebrate low spinal cat were investigated. Microinjected into the dorsal horn, morphine and Met-enkephalin depressed the nociceptive C-fiber reflex (CFR) without altering the short latency polysynaptic reflex. Microinjected into the ventral horn, morphine and Met-enkephalin facilitated the C-fiber and polysynaptic reflexes. Pretreatment of the cats with intravenous naltrexone (2 mg/kg) antagonized the depressant effects produced by dorsal horn intraspinal microinjections of morphine and Met-enkephalin. The excitant effects of ventral horn microinjections of morphine were not antagonized by naltrexone (2 mg/kg). These results support a hypothesis that the analgesic effects of morphine at the spinal cord level are due to interactions with opiate receptors in the dorsal horn.

Pharmacology of pain and analgesia

Physiological events involved in nociception and pain perception are examined. Substance P could be a primary afferent transmitter of certain nociceptive information. Transmission of this information can be modulated within the spinal cord by intrinsic and descending mechanisms. The intrinsic mechanism involves inhibitory opiate effects within substantia gelatinosa. Centres for descending systems are located in medulla and periaqueductal gray matter. They are activated by exogenous narcotic agonists, and by regional connections. Descending inhibitory pathways are serotonergic and noradrenergic. GABA and glycine are also possibly involved in antinociception. Narcotics have been shown to produce analgesia when administered to the intrathecal or epidural spaces of humans. These routes are still experimental. The place of clinical modification of transmitter system is discussed, but no conclusions or recommendations can be made at this early stage.